Valcyte 450mg Tablet

Adult Dosage Treatment of CMV retinitis Induction: 900 mg (two 450 mg tablets) twice a day for 21 days Maintenance: 900 mg (two 450 mg tablets) once a day Prevention of CMV disease in heart or kidney-pancreas transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation Prevention of CMV disease in kidney transplant patients 900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 200 days post-transplantation Pediatric Dosage Prevention of CMV disease in kidney transplant patients 4 months to 16 years of age Dose once a day within 10 days of transplantation until 200 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children) Prevention of CMV disease in heart transplant patients 1 month to 16 years of age Dose once a day within 10 days of transplantation until 100 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children) Valganciclovir tablets should be taken with food.

Directions from the U.S. FDA-approved label for Valganciclovir — your doctor or pharmacist may advise differently.

Valganciclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation. Hypersensitivity to valganciclovir or ganciclovir.

Excerpt from the U.S. FDA-approved label for Valganciclovir. Talk to a pharmacist or doctor before use.

Acute renal failure: Acute renal failure may occur in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients or those taking nephrotoxic drugs, reduce dosage in patients with renal impairment, and monitor renal function. 5.1 Hematologic Toxicity Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow failure including aplastic anemia have been reported in patients treated with valganciclovir or ganciclovir.

Warnings and precautions excerpt from the U.S. FDA-approved label for Valganciclovir — not a complete list. Talk to a pharmacist or doctor before use.

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Hematologic Toxicity. Acute Renal Failure. Impairment of Fertility. Fetal Toxicity. Mutagenesis and Carcinogenesis.

Excerpt from the U.S. FDA-approved label for Valganciclovir — not a complete list. Talk to a pharmacist or doctor about side effects.

Store at 25°C (77°F);

Storage information from the U.S. FDA-approved label for Valganciclovir.